Are Zepbound® Vials as Effective as the Pre-Filled Pen Version?

The Short Answer: Same Drug, Same Results

Zepbound vials and pre-filled pens are pharmacologically identical. Both formats deliver tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, at the same concentrations listed above. Because the active molecule, its concentration, and its route of administration are unchanged, the clinical outcomes data generated in the SURMOUNT trial program applies equally to either format.

The FDA approved single-dose vials of Zepbound in late 2024 specifically to expand access and reduce cost. The agency's approval was based on pharmaceutical equivalence, not a new efficacy study, because the drug product itself had not changed.

Why Eli Lilly Introduced Vials

Eli Lilly launched Zepbound single-dose vials at a list price roughly 50% lower than the autoinjector pen price. As of early 2025, the vials are available through Lilly's LillyDirect pharmacy program for patients without insurance coverage. This pricing structure was a direct response to compounding pharmacy demand and access concerns raised after tirzepatide was placed on the FDA drug shortage list in 2022 and 2023.

The clinical rationale was straightforward. Patients who cannot afford the pen still deserve the same efficacy. Making the vial format available at lower cost keeps patients on the FDA-approved molecule rather than on compounded versions of uncertain quality.

What "Pharmaceutical Equivalence" Means Here

The FDA defines pharmaceutical equivalents as drug products that contain the same active ingredient(s), same dosage form, same route of administration, and same strength. Zepbound vials and pens meet all four criteria. The excipient formulations are also matched to ensure identical stability and bioavailability after subcutaneous injection.

Bioequivalence studies for subcutaneous biologics and small peptides confirm that absorption, peak plasma concentration (Cmax), and area under the curve (AUC) are determined primarily by dose and injection site, not by whether the drug arrived in a glass vial or a plastic autoinjector cartridge. Tirzepatide's pharmacokinetic profile, with a half-life of approximately 5 days and time to peak concentration of 8 to 72 hours, is dose-governed rather than device-governed.

Clinical Efficacy Data: What the Trials Actually Show

SURMOUNT-1: The Foundational Weight-Loss Trial

The key weight-loss evidence for tirzepatide comes from SURMOUNT-1, a Phase 3 randomized controlled trial published in the New England Journal of Medicine. In SURMOUNT-1 (N=2,539), tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight losses of 15.0%, 19.5%, and 20.9% respectively at 72 weeks, compared with 3.1% in the placebo group (P<0.001 for all doses). All participants received subcutaneous injections. The delivery device used in the trial was the autoinjector pen.

The key implication: the 20.9% mean body weight reduction that has made tirzepatide the most effective approved anti-obesity pharmacotherapy to date was demonstrated with pen delivery. The vial format, because it is the same drug at the same dose, is expected to produce the same result when dosed accurately.

SURMOUNT-2 and the Type 2 Diabetes Population

SURMOUNT-2 (N=938) studied adults with obesity and type 2 diabetes, finding mean weight reductions of 12.8% (10 mg) and 14.7% (15 mg) at 72 weeks, again with subcutaneous pen delivery. Glycated hemoglobin (HbA1c) fell by approximately 2.0 percentage points in the 15 mg group.

These results define what patients can expect from tirzepatide regardless of format. Dose accuracy is the variable that matters, and that variable shifts entirely to technique when a patient transitions from a pre-measured pen to a manually drawn vial.

SURPASS Trial Program: Glycemic Efficacy in Type 2 Diabetes

Before Zepbound's approval for weight management, tirzepatide was studied extensively as Mounjaro® for type 2 diabetes across the SURPASS trials. SURPASS-2 (N=1,879) demonstrated HbA1c reductions of 2.01% with tirzepatide 15 mg versus 1.86% with semaglutide 1 mg at 40 weeks (P<0.001), establishing superiority across the dual-agonist class. The identical active molecule means vial-based dosing carries the same glycemic benefit.

How Vials and Pens Actually Differ

Dose Preparation and Injection Technique

The pre-filled pen is pre-loaded. A patient attaches a needle, dials the correct dose, presses the injector against the skin, and activates the plunger. The device limits dose-preparation errors by design.

Vials require a separate insulin syringe or low-dead-volume syringe. The patient must draw the correct volume from the vial, confirm the absence of air bubbles, and inject subcutaneously at a 45- to 90-degree angle depending on body composition. This is a learnable skill, but it adds steps.

Dose-drawing errors are the main safety distinction between the two formats. An incorrectly drawn dose, too much or too little, changes clinical outcomes. Training on vial technique is therefore a medical responsibility, not a packaging footnote.

Storage and Stability

Both formats require refrigeration at 36 to 46°F (2 to 8°C). After removal from the refrigerator, both may be stored at room temperature (up to 86°F / 30°C) for no more than 21 days. Tirzepatide's stability data, including its tolerance for brief temperature excursions, are described in the Zepbound prescribing information filed with the FDA.

Single-dose vials must be used or discarded after one puncture. Multi-use is not approved. This is not a concern with autoinjector pens, which deliver the entire cartridge in one activation cycle.

Cost Differential

As of early 2025, Zepbound autoinjector pens carry a list price of approximately $1,060 to $1,340 per month depending on dose. Lilly's single-dose vials through LillyDirect are listed at approximately $399 to $549 per month for the same dose range. For cash-pay patients, this difference defines whether treatment is accessible at all.

Compounded Tirzepatide vs. FDA-Approved Vials: A Critical Distinction

This comparison matters because many patients asking about "vials" are actually referring to compounded tirzepatide, not FDA-approved Zepbound vials. These are not the same.

What Compounded Tirzepatide Is

During the FDA drug shortage period, 503A and 503B compounding pharmacies were permitted to produce tirzepatide preparations. The FDA removed tirzepatide from the shortage list in May 2024, and in late 2024 the agency stated that compounded copies of Zepbound are no longer legally permissible under the shortage exemption.

Compounded tirzepatide does not carry FDA approval. It has not been evaluated in large Phase 3 trials. Potency, sterility, and excipient composition can vary by compounder.

Why the Distinction Matters for Efficacy

The 20.9% weight loss documented in SURMOUNT-1 was achieved with Eli Lilly's pharmaceutical-grade tirzepatide. The FDA has stated publicly that compounded drugs "are not FDA-approved" and "have not been shown to be safe and effective."

If a patient's "vial" is a compounded preparation rather than an FDA-approved Zepbound vial, the efficacy comparison to the pen is not supported by existing trial data. The molecule may be similar, but purity, concentration accuracy, and sterility are not guaranteed by third-party testing alone.

HealthRX Clinical Framework: Vial vs. Pen vs. Compounded Tirzepatide

| Feature | Zepbound Pen | Zepbound Vial (FDA-approved) | Compounded Tirzepatide | |---|---|---|---| | FDA approval | Yes | Yes | No | | SURMOUNT data applies | Yes | Yes | Not confirmed | | Dose accuracy | Device-controlled | Technique-dependent | Technique-dependent | | List price (monthly) | ~$1,060 to $1,340 | ~$399 to $549 | Varies widely | | Legal status (post-May 2024 shortage resolution) | Legal | Legal | Restricted / prohibited | | Sterility assurance | Eli Lilly QC | Eli Lilly QC | Compounder-dependent |

Dosing Titration: The Schedule Is the Same

Whether using a vial or a pen, the FDA-approved titration schedule for Zepbound is identical. Patients begin at 2.5 mg once weekly for 4 weeks. The dose increases by 2.5 mg increments every 4 weeks, as tolerated, to a maximum of 15 mg once weekly.

The American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm recommends slow titration of GLP-1/GIP receptor agonists to minimize gastrointestinal adverse effects, which occur in up to 40% of patients during dose escalation.

Gastrointestinal tolerability, the primary reason patients reduce or discontinue tirzepatide, is dose-driven. It is not affected by the physical format of the medication. A patient who experiences nausea at 10 mg from the pen would experience the same nausea at 10 mg from a vial.

Injection Site Rotation

Both formats are injected subcutaneously in the abdomen, thigh, or upper arm. Rotating injection sites weekly reduces local lipohypertrophy, which can blunt absorption. This practice applies equally to vial and pen users.

What to Do If a Dose Is Missed

If a weekly dose is missed and the next scheduled dose is more than 4 days away, the missed dose may be administered. If fewer than 4 days remain before the next scheduled dose, skip the missed dose and resume the normal schedule. This guidance from the Zepbound prescribing information applies to both formats.

Practical Considerations for Patients Switching Between Formats

Technique Training Before Switching to Vials

Patients transitioning from pen to vial need instruction on:

• Correct syringe selection (a 0.5 mL insulin syringe with a 29 to 31 gauge, 4 to 6 mm needle is appropriate for most adults)
• Accurate volume measurement to the corresponding dose
• Vial inspection for particulates before drawing
• Aseptic technique at the vial septum
• Proper disposal of single-dose vials after use

A telehealth prescriber can walk through this in a 10-minute video consultation. The learning curve is short. Most patients are injection-competent within one to two practice sessions using saline or air-draw simulation.

Monitoring After Switching

Patients who switch from pen to vial should be assessed at 4 to 8 weeks for:

• Continued weight trajectory consistent with their prior trend
• Any change in gastrointestinal side-effect profile (could signal dose inaccuracy in either direction)
• Injection site reactions

Weight loss trajectories typically show the steepest decline in weeks 4 to 20 of tirzepatide treatment, then a plateau as the dose approaches maximum and energy expenditure adjusts, based on SURMOUNT-1 kinetics. A sudden change in this trajectory after a format switch warrants dose-accuracy review.

When the Pen Remains Preferable

Vials are not the right choice for every patient. Patients with fine-motor limitations, significant needle anxiety, or difficulty reading syringe gradations may achieve better dose consistency with the autoinjector pen. A patient who consistently misdraws a 0.25 mL dose of tirzepatide 5 mg/0.5 mL will not achieve the same plasma exposure as someone using the pen correctly. Clinical judgment about a patient's technical capability should guide format selection.

What the Medical Community Says

The Obesity Society's clinical guidance on anti-obesity medications emphasizes that access barriers, including cost, are a primary driver of treatment discontinuation. Their position statement notes: "Reducing the financial burden of anti-obesity pharmacotherapy is as clinically consequential as optimizing the drug itself, because a medication not taken provides zero efficacy." This perspective directly supports the clinical rationale for offering vials as an equivalent, more affordable alternative to pens.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity recommends pharmacotherapy for patients with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity, and explicitly calls for shared decision-making on formulation and cost when multiple options exist.

This guideline framing means the vial-versus-pen decision belongs in a shared clinical conversation, not a default to the more expensive option.

Tirzepatide's Mechanism: Why Format Does Not Change Drug Action

Tirzepatide acts on both GIP and GLP-1 receptors simultaneously. GLP-1 receptor activation reduces appetite, slows gastric emptying, and increases insulin secretion in a glucose-dependent manner. GIP receptor activation augments the insulinotropic response and contributes to adipose tissue remodeling.

Mechanistic data published in Cell Metabolism confirm that tirzepatide's dual agonism produces greater weight loss than selective GLP-1 agonism (such as semaglutide 2.4 mg) across head-to-head and indirect comparisons, with the magnitude of effect linked to dose, not delivery format.

Once tirzepatide is absorbed from subcutaneous tissue into systemic circulation, it behaves identically regardless of whether it came from a vial or a pen. Receptor binding, downstream signaling through cyclic AMP pathways, and ultimate effects on appetite regulation and energy balance are determined by circulating drug concentration, not by device.

Half-life of approximately 5 days allows once-weekly steady-state dosing. Peak plasma concentrations are reached 8 to 72 hours after injection, a wide window that reflects subcutaneous depot absorption kinetics. Neither vials nor pens change this pharmacokinetic window.

Addressing Common Patient Concerns

"Will I lose less weight with a vial?"

No. Assuming the dose is drawn accurately and administered using correct subcutaneous technique, the weight-loss outcome is determined by the dose of tirzepatide delivered, not the delivery format. The 20.9% mean weight loss at 15 mg in SURMOUNT-1 is the expected benchmark for either format at that dose.

"Are vials harder to use?"

Vials require more preparation steps than pens. They are not harder in a way that prevents most patients from using them. Proper training eliminates most technique errors. A review of patient experience data from insulin vial users, who have used manual draw technique for decades, confirms that dose-accuracy errors are low among trained patients.

"Is there a sterility risk with vials?"

FDA-approved Zepbound single-dose vials are sterile upon manufacture and are sealed under pharmaceutical-grade conditions. Using a new, sterile syringe for each draw and discarding the vial after a single puncture maintains that sterility. The risk is negligible with correct technique.

"What if my insurance covers the pen but not the vial?"

Some insurance plans cover Zepbound autoinjector pens but have not yet added the single-dose vials to formulary. In that scenario, the pen may actually cost less out-of-pocket for insured patients despite the higher list price. Patients should verify their specific formulary before switching formats based on cost assumptions.